Perimenopause and biological age: which markers change before menopause

Most women learn about menopause as a single event: a final period, a calendar date, and a list of symptoms. The reality is messier. The years before that date — perimenopause — are when your biology actually starts to shift, and emerging research shows your biological age can pull ahead of your chronological age during this window.

If you are in your late 30s or 40s and noticing changes in sleep, recovery, weight distribution, or mood, you are not imagining it. A 2025 cohort study found that women in the menopausal transition showed measurably greater acceleration in comprehensive biological age — including liver, metabolic, and kidney aging — compared with women who remained pre-menopausal. The transition is not neutral.

The good news: the markers that change during perimenopause are the same ones that drive longevity. Track them now and you have a window to intervene before menopause locks in faster aging.

What you’ll learn:

• Which hormone markers shift first during perimenopause and in what order
• How perimenopause accelerates biological age across multiple organ systems
• The blood biomarkers and wearable metrics that flag aging during the transition
• Practical steps to protect your biological age in your 40s

---

What is perimenopause?

Perimenopause is the multi-year transition that ends with menopause (defined retrospectively as 12 consecutive months without a period). It typically begins 8–10 years before the final menstrual period, most often in the mid-40s, though it can start in the late 30s.

Quick definition: Perimenopause is the hormonal transition phase before menopause, marked by erratic estrogen and progesterone levels and rising follicle-stimulating hormone (FSH). It can last 4–10 years.

Unlike menopause itself, perimenopause is dynamic. Hormone levels do not fall in a smooth curve — they swing, sometimes producing estrogen surges 20–30% higher than reproductive-age peaks before eventually declining. That volatility is why the perimenopause years can feel harder to manage than post-menopause, when levels stabilize at a new (lower) baseline.

Why perimenopause matters for your biological age

The menopausal transition is not just reproductive — it is systemic. Research published in PNAS showed that menopause itself accelerates epigenetic aging in blood by roughly 6%, and that earlier menopause is associated with greater age acceleration. More recent 2025 work in BMC Medicine extended this finding, showing that the transition itself — not just the post-menopausal state — drives measurable acceleration in liver, kidney, and metabolic biological age scores.

In practice: your PhenoAge or KDM biological age score can pull ahead of your chronological age during your 40s, often before you notice major symptoms.

For a broader view of how menopause continues this trajectory after the transition ends, see our deep dive on menopause and biological age acceleration.

If the visible change is waist or scale weight, weight gain in perimenopause vs aging gives a narrower decision path.

If the confusing part is whether estrogen or progesterone is driving the change, the comparison guide on estrogen vs progesterone in perimenopause separates broad aging effects from earlier sleep and cycle signals.

---

The science behind perimenopause and aging

The hormonal cascade — which markers change first

Perimenopause unfolds in a specific sequence. Understanding the order matters because the earliest changes happen years before periods become irregular.

1. AMH (anti-Müllerian hormone) — the first to fall

AMH reflects your ovarian reserve, the pool of follicles still available for ovulation. It peaks in your mid-20s and declines steadily. AMH is the first hormone to show a measurable change as you approach perimenopause, often dropping years before any cycle irregularity appears. A low AMH does not mean you are infertile tomorrow, but it signals where you are on the reproductive aging curve. If you are weighing fertility preservation, our egg-freezing guide by age explains what AMH can predict and where its limits begin.

2. FSH (follicle-stimulating hormone) — the next to rise

As ovarian reserve declines, the pituitary gland compensates by releasing more FSH to try to stimulate follicles. FSH starts climbing in late reproductive age and can be elevated for years before the final period. A single FSH reading is unreliable during perimenopause because it fluctuates cycle-to-cycle; serial measurements are far more informative.

3. Inhibin B — the quiet middle marker

Inhibin B, produced by developing follicles, declines roughly in parallel with the FSH rise. It is less commonly measured clinically but tracks the same underlying process.

4. Estradiol — the late and erratic shifter

Contrary to the popular narrative, estradiol does not simply decline through perimenopause. It typically rises in early to mid-perimenopause — sometimes 20–30% above pre-menopausal peaks — before falling sharply in the final 1–2 years. This is why hot flashes and heavy bleeding can appear before any “low estrogen” symptoms.

For a head-to-head comparison of which of these tests is most useful in clinical practice, see FSH vs estradiol vs AMH in perimenopause.

How perimenopause affects your body beyond reproduction

The same hormonal volatility that drives hot flashes also nudges nearly every system that biological-age calculators measure:

• Cardiometabolic: Insulin sensitivity drops; visceral fat increases even at stable weight; LDL and ApoB tend to rise as estrogen falls.
• Inflammation: CRP and other inflammatory markers climb, partly because estrogen has anti-inflammatory effects that fade.
• Kidney function: eGFR and cystatin C show accelerated decline through the transition.
• Bone and muscle: Lean mass loss accelerates; bone turnover increases.
• Sleep architecture: Deep sleep and REM duration both shorten; HRV drops; resting heart rate often rises 2–5 bpm.

These shifts are exactly the inputs that PhenoAge, KDM, and wearable-derived biological-age models use. That is why your composite biological age score can move 1–3 years in either direction during this window depending on how you respond.

---

The 7 biomarkers that flag perimenopausal aging first

Most clinicians measure FSH and call it done. The biomarkers below give you a far better picture of how perimenopause is affecting your healthspan — and they are all standard, affordable tests.

1. AMH (anti-Müllerian hormone)

Why it matters: First marker to change. Tells you where you are on the reproductive aging curve, which forecasts when systemic changes will begin.

How to interpret:

• Above 1.0 ng/mL: typical reproductive range
• 0.5–1.0 ng/mL: late reproductive / early perimenopause
• Below 0.5 ng/mL: perimenopause likely
• Below 0.1 ng/mL: menopause approaching within ~5 years

When to test: Any time in the cycle — AMH does not fluctuate with cycle phase.

2. FSH (follicle-stimulating hormone)

Why it matters: Tracks the pituitary response to declining ovarian reserve. Reliable when checked serially.

How to interpret: Persistently above 25 IU/L on day 2–5 of the cycle suggests perimenopause. A single high value is not diagnostic.

When to test: Days 2–5 of the menstrual cycle, repeated across 2–3 cycles.

3. Estradiol

Why it matters: Captures the erratic estrogen swings characteristic of mid-perimenopause.

How to interpret: Highly variable. Symptoms (heavy bleeding, breast tenderness, mood shifts) often correlate better than a single number.

Hormone-related tenderness is often diffuse or cyclical; new focal breast pain or associated breast changes should be evaluated on their own merits.

When to test: With FSH, days 2–5 of the cycle.

4. Fasting insulin and HbA1c

Why it matters: Insulin resistance can rise sharply during perimenopause, well before fasting glucose moves. Fasting insulin catches this earliest.

How to interpret:

• Fasting insulin: optimal below 5 µIU/mL (for age-banded targets across your 40s, 50s, and 60s, see fasting insulin normal range by age)
• HbA1c: optimal below 5.4%

For more on why insulin is the earliest signal, see fasting insulin as a biomarker for longevity.

5. High-sensitivity CRP (hs-CRP)

Why it matters: Inflammation climbs as estrogen’s anti-inflammatory effect wanes. Elevated hs-CRP feeds into PhenoAge and several biological-age clocks.

How to interpret: Optimal below 1.0 mg/L. Above 3.0 mg/L signals significant inflammatory load.

6. ApoB and LDL-cholesterol

Why it matters: Cardiometabolic risk accelerates through perimenopause. ApoB rises before LDL changes are dramatic and is the more accurate predictor.

How to interpret: ApoB below 80 mg/dL is optimal for cardiovascular longevity; above 100 mg/dL warrants action.

7. PhenoAge biomarker panel

Why it matters: PhenoAge combines 9 routine blood markers — albumin, creatinine, glucose, hs-CRP, lymphocyte %, MCV, RDW, alkaline phosphatase, and WBC count — into a single biological-age estimate. It is the most accessible composite measure during perimenopause.

How to interpret: A PhenoAge that runs more than 2 years above your chronological age during perimenopause suggests the transition is accelerating aging, and is a strong signal to intervene.

For the full methodology, see how PhenoAge and KDM use blood tests to estimate biological age.

---

How to track perimenopause aging with wearables

Wearables capture daily shifts that blood tests miss. During perimenopause, three metrics deserve attention:

Key wearable metrics to monitor

Metric	What changes in perimenopause	Optimal pattern
Heart rate variability (HRV)	Falls 5–15 ms on average	Stable or rising trend, not absolute number
Resting heart rate	Rises 2–5 bpm, often before symptoms	Flat or falling 3-month trend
Deep + REM sleep	Both shorten; fragmentation rises	Maintain 1.5–2 hours combined deep + REM
Skin temperature variability	Cycle-related swings amplify; nocturnal spikes signal hot flashes	Tighter range = better thermoregulation

These wearable signals form the basis of wearable-derived biological-age models. For how blood tests and wearables compare as inputs, see biological age from blood tests vs wearables.

If the wearable signal that changed first is cardio fitness, the focused guide on VO2 max and menopause explains how sleep, vascular function, body composition, and training load can move the estimate during midlife.

Cycle tracking still matters

Even when cycles become irregular, length variability is one of the clearest perimenopause signals. A change of 7+ days from one cycle to the next is a recognized clinical marker of the transition.

---

How SuperAge helps you navigate perimenopause

Tracking seven biomarkers, multiple wearable metrics, and cycle patterns manually is overwhelming, especially when each one tells you something different about your aging trajectory. SuperAge consolidates these signals into a single biological-age score that updates as your data changes.

Automatic biomarker integration

Connect your Apple Health data and your most recent blood work, and SuperAge calculates PhenoAge and KDM biological age automatically. You see whether your composite score is ahead of, behind, or tracking your chronological age — and which markers are pulling it in either direction.

Wearable-driven daily signal

SuperAge reads HRV, resting heart rate, sleep stages, and VO2 max directly from Apple Watch. During perimenopause, these are exactly the metrics most likely to drift first, and seeing them as a trend rather than a daily number is what makes them actionable.

Trend visualization across the transition

Perimenopause is a multi-year process. SuperAge stores your biological age over time so you can see whether interventions — strength training, sleep changes, supplementation — are actually moving the needle, rather than guessing.

---

Frequently asked questions

At what age should I start tracking perimenopause markers?

By age 35–40, even if you have no symptoms. AMH and a baseline PhenoAge panel give you a reference point before changes begin, which is more informative than a first test once symptoms are obvious.

Can perimenopause actually make my biological age higher than my chronological age?

Yes, this is now well documented. The 2025 BMC Medicine cohort study showed measurable acceleration in composite, liver, kidney, and metabolic biological age during the transition compared with women who remained pre-menopausal. The size of the gap is influenced by lifestyle factors and how rapidly the transition unfolds.

Does hormone replacement therapy slow biological aging during perimenopause?

Evidence is mixed but suggestive. Some studies show MHT (menopausal hormone therapy) attenuates epigenetic age acceleration when started during the transition, particularly for cardiovascular and bone biomarkers. This is a clinical decision that depends on personal and family medical history — consult a clinician.

Is irregular sleep during perimenopause a sign of accelerated aging?

Persistent sleep fragmentation, reduced deep sleep, and rising resting heart rate during sleep are all linked to faster biological aging. They are also reversible signals — improvements in sleep hygiene, cooling the bedroom, and reducing evening alcohol typically move HRV and RHR within weeks.

Can I improve my biological age during perimenopause, or am I locked in?

You can. The same biomarkers that accelerate during perimenopause respond strongly to resistance training, protein intake (1.6–2.2 g/kg/day, or roughly 0.7–1.0 g per pound of bodyweight), sleep quality, and stress management. Many women see their PhenoAge improve through the transition with consistent intervention.

---

Key takeaways

• AMH falls first, FSH rises next, estradiol becomes erratic last — the order matters because the earliest markers shift years before periods become irregular
• Perimenopause measurably accelerates biological age across multiple organ systems, not just the reproductive one
• Seven markers give you a complete picture: AMH, FSH, estradiol, fasting insulin, hs-CRP, ApoB, and a PhenoAge panel
• Wearable trends in HRV, resting heart rate, and sleep architecture often shift before symptoms appear and are highly responsive to intervention
• Tracking now beats tracking later — your 40s are a window where small interventions show outsized effects on biological age

---

Start tracking your perimenopause biology today

Perimenopause is the most data-rich and most overlooked decade in women’s health. The biomarkers and wearable signals are already in your Apple Health data and your most recent lab panel — they just need to be read together. Tracking them as a single biological-age trend transforms a vague, decade-long transition into a clear feedback loop you can actually act on.

Ready to see where you actually stand? Download SuperAge and start tracking your biological age through perimenopause and beyond.

---

References

1. Levine M, et al. — “Menopause accelerates biological aging” (PNAS, 2016). Epigenetic clock acceleration in blood linked to menopausal status and timing.
2. Kresovich JK, et al. — “Menopausal status, transition, and age at menopause with accelerated biological aging across multiple organ systems” (BMC Medicine, 2025). Cohort evidence that the transition itself drives organ-specific aging.
3. Burger HG, et al. — “Hormonal changes in the menopausal transition” — describes the AMH–FSH–inhibin B–estradiol sequence.
4. Hale GE, et al. — “Endocrine features of menopausal transition” — documents the mid-perimenopausal estradiol surge.
5. Liu Y, et al. — “Postmortem tissue biomarkers of menopausal transition” (Molecular Psychiatry, 2025). Identifies 14 significant systemic biomarkers of the transition.

---

The information provided does not replace professional medical advice. Consult your healthcare provider before making decisions about hormone testing, supplementation, or therapy. Last updated: 2026-05-13. This article is regularly reviewed to ensure accuracy.